GLP1R and type 2 diabetes mellitus: GLP-1 receptor agonists (RAs) were developed for treatment of hyperglycemia in T2DM patients; the LEADER study reported that liraglutide improved CVD outcomes in high-risk diabetic patients with previous CV events through different pathways [129].